Adams, Olivia Joan; Stanczak, Michal A; von Gunten, Stephan; Läubli, Heinz (2018). Targeting sialic acid-Siglec interactions to reverse immune suppression in cancer. Glycobiology, 28(9), pp. 640-647. Oxford University Press 10.1093/glycob/cwx108
|
Text
von Gunten_Targeting sialic acidSiglec interactions to reverse immune suppression in cancer.pdf - Published Version Available under License Publisher holds Copyright. Download (283kB) | Preview |
Changes in sialic acids in cancer have been observed for many years. In particular, the increase of sialoglycan density or hypersialylation in tumors has been described. Recent studies have identified mechanisms for immune evasion based on sialoglycan interactions with immunoregulatory Siglec receptors that are exploited by tumor cells and microorganisms alike. Siglecs are mostly inhibitory receptors similar to known immune checkpoints including PD-1 or CTLA-4 that are successfully targeted with blocking antibodies for cancer immunotherapy. Here, we summarize the known changes of sialic acids in cancer and the role Siglec receptors play in cancer immunity. We also focus on potential ways to target these Siglec receptors or sialoglycans in order to improve anti-cancer immunity.
Item Type: |
Journal Article (Review Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Pharmacology |
UniBE Contributor: |
von Gunten, Stephan |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
0959-6658 |
Publisher: |
Oxford University Press |
Language: |
English |
Submitter: |
Jana Berger |
Date Deposited: |
21 Mar 2018 09:26 |
Last Modified: |
20 Dec 2022 12:25 |
Publisher DOI: |
10.1093/glycob/cwx108 |
PubMed ID: |
29309569 |
Uncontrolled Keywords: |
N-acetyl-neuraminic acid N-glycolyl-neuraminic acid blocking antibodies cancer immunotherapy hypersialylation immune evasion |
BORIS DOI: |
10.7892/boris.111502 |
URI: |
https://boris.unibe.ch/id/eprint/111502 |
Actions (login required)
 |
Edit item |